LinusBio precision exposome medicine program follows the evolving precision medicine paradigm:

I. patient group stratification, disease & patient phenotyping
II. biomarker & diagnostics, patient-journey monitoring
III. characterization of pathways and biological mechanisms for target discovery
IV. drug development and clinical-trial design

Milestone collaborations achieved on two fronts

  • ASD pharmaceutical / clinical trials for older ASD patients
  • Non-pharmaceutical / nutraceuticals for high-risk ASD infants

Near-future deliverables for neurodevelopmental diseases:

  • First-in-class StrandDx™-ASD biomarker & diagnostic for autism.
  • FDA Breakthrough Designation for ASD, awarded.
  • Market access & reimbursement program for deNovo in vitro diagnostic.

Next breakthrough programs

  • Amyotrophic lateral sclerosis (ALS)
  • Inflammatory bowel disease (IBD)
  • Attention deficit hyperactive disorder (ADHD)
  • Psychosis/schizophrenia
  • Renal disease
  • Pediatric cancer